Introduction to Depression Trials

In this work, we propose a stochastic binary synaptic model where the cumulative probability of the weight change evolves in a sigmoidal fashion with potentiation or depression trials, which can be implemented using a pair of switching devices consisting of serially connected multiple binary memristors.

How parents were involved in treatments varied greatly, with at least 13 different combinations of ways of involving parents in the anxiety trials and seven different combinations in the depression trials.

Conclusions: Both the magnitude and predictors of placebo response in pediatric depression trials do not replicate across anxiety and OCD.

’s approach is unusual because in depression trials we, the researchers, the ones who design the measurement scales and trials, are usually our own source of normativity.

3 It remains paradoxical that mood stabilizers to treat acute bipolar depression yield remarkably small effect sizes and yet the placebo effect in bipolar depression trials remains strikingly high.

How parents were involved in treatments varied greatly, with at least 13 different combinations of ways of involving parents in 62 anxiety trials and 7 different combinations among 11 depression trials.

This article details an example in which interview data collected during three primary care depression trials were brought together to explore trial participants’ study and treatment journeys.

These findings have important implications for the interpretation of active treatments and placebo response in depression trials.

We still need to figure out what constitutes a meaningful change in scores and we might have to stick with relatively arbitrary clinical indices such as response (for example, the 50% reduction in scores often used in depression trials) which are also used for other dimensional health conditions (such as hypertension), or we could calibrate a meaningful change in scores against patient-defined global ratings to generate a “minimal clinically important difference”.

Trial duration was positively associated with the magnitude of placebo improvement in depression trials but negatively associated with the magnitude of placebo improvement in anxiety and obsessive-compulsive disorder trials.